Acimmune SA (ACIU) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Acimmune SA (ACIU:NASDAQ), powered by AI.
- Current Price
- $2.31
- P/E Ratio
- -3.3
- Market Cap
- 233M
- Sector
- Healthcare
What is the Acimmune SA stock price forecast?
Acimmune SA is currently trading at $2.31. View real-time AI analysis on Alpha Lenz.
What is Acimmune SA insider trading activity?
View the latest insider trading data for Acimmune SA on Alpha Lenz.
What is Acimmune SA's P/E ratio?
Acimmune SA's P/E ratio is -3.3.
Acimmune SA
NASDAQ · ACIU“Acimmune SA trades at a P/E of -3.3 (undervalued) with modest ROE of -89.7%.”
Ask for details →Company Overview
Acimmune SA is a Swiss biotechnology firm that specializes in the development of therapeutics aimed at preventing and treating neurodegenerative diseases. The company is at the forefront of combating conditions such as Alzheimer's and Parkinson's disease through its innovative pipeline of proprietary technology platforms. These platforms focus on targeting misfolded proteins that play a crucial role in the pathology of neurodegenerative disorders. Acimmune collaborates with major pharmaceutical companies to bolster its research and enhance the effectiveness of its therapeutic solutions. Headquartered in Lausanne, Switzerland, the company is pivotal in the biopharmaceutical sector, particularly in advancing treatments for diseases that currently have limited or no cure. By focusing on precision medicine, Acimmune contributes significantly to the field of neuroscience and has a strong potential impact on improving long-term health outcomes for aging populations worldwide.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Acimmune SA trades at a P/E of -3.3 (undervalued) with modest ROE of -89.7%.”
Ask for details →Frequently Asked Questions
Acimmune SA (ticker: ACIU) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 133 employees. Market cap is $233M.
The current price is $2.31 with a P/E ratio of -3.3x and P/B of 5.19x.
ROE is -89.65% and operating margin is -1927.32%. Annual revenue is $4M.